Roberto Andrés Riquelme-Neira

Dr. Roberto Andrés Riquelme-Neira

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Vaccine
Verified
Journal Article
Closed access
RRRoberto Andrés Riquelme-Neira
Roberto Andrés Riquelme-Neira
ARAngello Retamal-Díaz
Angello Retamal-Díaz
FAFrancisca Acuña
Francisca Acuña
PRPablo Riquelme
Pablo Riquelme
ARAlejandra Rivera
Alejandra Rivera
AOAngel Oñate
Angel Oñate

27 August 2014 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
ARAngello Retamal-Díaz
Angello Retamal-Díaz
RRRoberto Andrés Riquelme-Neira
Roberto Andrés Riquelme-Neira
DSDarwin Sáez
Darwin Sáez
ARAlejandra Rivera
Alejandra Rivera
PFPablo Fernández
Pablo Fernández
AOAngel Onate
Angel Onate
This study was conducted to evaluate the immunogenicity and protective efficacy of a DNA vaccine encodingBrucella abortusCu,Zn superoxide dismutase (SOD) using the Toll-like receptor 2/6 agonistS-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene glycol (BPPcysMPEG) as an adjuvant. Intranasal coadministration of BPPcysMPEG with a plasmid carrying the SOD-encoding gene (pcDNA-SOD) into BALB/c mice elicited antigen-specific humoral and cellular immune responses. Humoral responses were characterized by the stimulation of IgG2a and IgG1 and by the presence of SOD-specific secretory IgA in nasal and bronchoalveolar lavage fluids. Furthermore, T-cell proliferative responses and increased production of gamma interferon were also observed upon splenocyte restimulation with recombinant SOD. Cytotoxic responses were also stimulated, as demonstrated by the lysis of RB51-SOD-infected J774.A1 macrophages by cells recovered from immunized mice. The pcDNA-SOD/BPPcysMPEG formulation induced improved protection against challenge with the virulent strainB. abortus2308 in BALB/c mice over that provided by pcDNA-SOD, suggesting the potential of this vaccination strategy againstBrucellainfection.

20 January 2016 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
RRRoberto Andrés Riquelme-Neira
Roberto Andrés Riquelme-Neira
ARAlejandra Rivera
Alejandra Rivera
DSDarwin Sáez
Darwin Sáez
PFPablo Fernández
Pablo Fernández
GOGonzalo Osorio
Gonzalo Osorio
AOAngel Onate
Angel Onate
Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is the predominant causative agent of hemorrhagic colitis in humans and is the cause of haemolytic uraemic syndrome and other illnesses. Cattle have been implicated as the main reservoir of this organism. Here, we evaluated the immunogenicity and protective efficacy of a DNA vaccine encoding conserved sequences of truncated EHEC factor for adherence-1 (efa-1’) in a mouse model. Intranasal administration of plasmid DNA carrying the efa-1’ gene (pVAXefa-1’) into C57BL/6 mice elicited both humoral and cellular immune responses. In animals immunized with pVAXefa-1`, EHEC-secreted protein-specific IgM and IgG antibodies were detected in sera at day 45. Anti-EHEC-secreted protein sIgA was also detected in nasal and bronchoalveolar lavages. In addition, antigen-specific T-cell-proliferation, IL-10 and IFN-γ were observed upon re-stimulation with either heat-killed bacteria or EHEC-secreted proteins. Vaccinated animals were also protected against challenge with E. coli O157:H7 strain EDL933. These results suggest that DNA vaccine encoding efa-1´ have therapeutic potential in interventions against EHEC infections. This approach could lead to a new strategy in the production of vaccines that prevent infections in cattle.

1 August 2014 in Veterinary Microbiology
Verified
Journal Article
Closed access
LOLuisa Ortiz-Román
Luisa Ortiz-Román
RRRoberto Andrés Riquelme-Neira
Roberto Andrés Riquelme-Neira
RVRoberto Vidal
Roberto Vidal
AOAngel Onate
Angel Onate

15 March 2025 in Animals
Verified
Journal Article
Open access
PDF file
Anne-Sophie HascoëtAnne-Sophie Hascoët
Anne-Sophie Hascoët
PTPaulina Torres-Celpa
Paulina Torres-Celpa
RRRoberto Andrés Riquelme-Neira
Roberto Andrés Riquelme-Neira
HHHéctor Hidalgo
Héctor Hidalgo
Avian coccidiosis remains a problematic challenge in poultry farms worldwide, with increasing concerns about resistance to conventional anticoccidial drugs, highlighting the need for alternative control strategies. A total of 256 male broilers (Ross 308), 1 day old, were randomly assigned to four experimental groups (eight replicates, each containing eight chickens) to evaluate the effectiveness of a phytogenic supplement against Eimeria spp. At 14 days, broilers were challenged via oral gavage with a mixture of six strains of live Eimeria spp. oocysts (4.0 × 104 Eimeria spp. oocysts per bird). The groups included a negative control (no anticoccidials or challenge), a positive control (coccidial challenge, no anticoccidials), a phytogenic-supplemented diet based on alkaloids and flavonoids, and a diet with anticoccidials (narasin and nicarbazin). Fecal samples were collected for oocyst counts from day 14 to 23, and at 23 days (9 days post-infection), intestinal lesions and mucosa measurements were evaluated. The oocyst counts in the phytogenic and anticoccidial groups were significantly lower than in the positive control (with a reduction of 61.3% and 71.6%, respectively, compared to the positive control) (p < 0.05), with no significant differences between the phytogenic supplement and anticoccidials. The phytogenic supplement provided intermediate protection based on histopathological scores with a significantly lower histopathology score than the positive control but significantly higher than the negative control (p < 0.05). No differences in body weight, feed intake, feed conversion ratio, or mortality were observed across groups during the trial, likely due to the moderate challenge applied. In conclusion, the phytogenic supplement demonstrated anticoccidial activity comparable to narasin and nicarbazin without compromising productivity, warranting further research into its mechanisms, resistance impact, and commercial application.

Verified
Journal Article
Open access
PDF file
RRRoberto Andrés Riquelme-Neira
Roberto Andrés Riquelme-Neira
RWRomina Walker-Vergara
Romina Walker-Vergara
JFJoan Antoni Fernández-Blanco
Joan Antoni Fernández-Blanco
PVPatrocinio Vergara
Patrocinio Vergara
Mast cells (MCs) are involved in several immune-related responses, including those in bacterial infections, autoimmune diseases, inflammatory bowel diseases, and cancer, among others. MCs identify microorganisms by pattern recognition receptors (PRRs), activating a secretory response. Interleukin (IL)-10 has been described as an important modulator of MC responses; however, its role in PRR-mediated activation of MC is not fully understood. We analyzed the activation of TLR2, TLR4, TLR7 and Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) in mucosal-like MCs (MLMCs) and peritoneum-derived cultured MCs (PCMCs) from IL-10−/− and wild-type (WT) mice. IL-10−/− mice showed a reduced expression of TLR4 and NOD2 at week 6 and TLR7 at week 20 in MLMC. In MLMC and PCMC, TLR2 activation induced a reduced secretion of IL-6 and TNFα in IL-10−/− MCs. TLR4- and TLR7-mediated secretion of IL-6 and TNFα was not detected in PCMCs. Finally, no cytokine release was induced by NOD2 ligand, and responses to TLR2 and TLR4 were lower in MCs at 20 weeks. These findings indicate that PRR activation in MCs depends on the phenotype, ligand, age, and IL-10.